文献速递临床试验与 GCP基础与转化研究

单纯血管内治疗与静脉阿替普酶联合血管内治疗对急性缺血性卒中患者功能独立的影响:DEVT随机临床试验

Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

DEVT多中心随机非劣效试验纳入234例前循环近端大血管闭塞且发病4.5小时内符合静脉溶栓条件的卒中患者,比较单纯血管内取栓与静脉阿替普酶联合取栓。症状性颅内出血与90天死亡率组间无显著差异。

要点

  • 发病4.5小时内前循环近端大血管闭塞患者,单纯血管内取栓在90天功能独立上非劣于静脉阿替普酶联合取栓。
  • 症状性颅内出血(6.1% vs 6.8%)与90天死亡率(17.2% vs 17.8%)组间无显著差异。
  • 结果需结合所选非劣效界值(-10%)的临床可接受性解读,且试验因有效提前终止。

核心结论

  • 在前循环近端大血管闭塞且发病4.5小时内的缺血性卒中患者中,单纯血管内治疗对比静脉阿替普酶联合血管内治疗,达到90天功能独立的非劣效统计阈值。
  • 上述结论应结合所选非劣效界值的临床可接受性进行解读。

研究设计与样本

  • 多中心、随机、非劣效试验,在中国33家卒中中心开展。
  • 纳入234例18岁及以上、前循环近端颅内闭塞、发病4.5小时内且符合静脉溶栓条件的患者。
  • 入组时间为2018年5月20日至2020年5月2日,随访90天,最终随访至2020年7月22日。
  • 116例随机至单纯血管内取栓组,118例随机至静脉溶栓联合血管内取栓组。
  • 计划样本970例,因有效在234例随机后提前终止。

主要发现

  • 症状性颅内出血发生率:单纯血管内治疗组6.1%,联合治疗组6.8%,差异-0.8%(95%CI -7.1%至5.6%)。
  • 90天死亡率:单纯血管内治疗组17.2%,联合治疗组17.8%,差异-0.5%(95%CI -10.3%至9.2%)。

关键数值与推荐

  • 主要终点为90天功能独立,定义为改良Rankin量表评分0-2分(范围0分无症状至6分死亡)。
  • 非劣效界值为-10%。

临床怎么用

  • 对于发病4.5小时内前循环近端大血管闭塞且符合静脉溶栓条件的患者,单纯血管内取栓可作为静脉阿替普酶联合取栓的替代策略。
  • 临床决策需结合本试验所选非劣效界值的临床可接受性及提前终止的局限性综合判断。

局限性

  • 试验因有效在计划970例中仅随机234例后提前终止。
  • 非劣效界值-10%的临床可接受性需结合临床背景解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: For patients with large vessel occlusion strokes, it is unknown whether endovascular treatment alone compared with intravenous thrombolysis plus endovascular treatment (standard treatment) can achieve similar functional outcomes. OBJECTIVE: To investigate whether endovascular thrombectomy alone is noninferior to intravenous alteplase followed by endovascular thrombectomy for achieving functional independence at 90 days among patients with large vessel occlusion stroke. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, noninferiority trial conducted at 33 stroke centers in China. Patients (n = 234) were 18 years or older with proximal anterior circulation intracranial occlusion strokes within 4.5 hours from symptoms onset and eligible for intravenous thrombolysis. Enrollment took place from May 20, 2018, to May 2, 2020. Patients were enrolled and followed up for 90 days (final follow-up was July 22, 2020). INTERVENTIONS: A total of 116 patients were randomized to the endovascular thrombectomy alone group and 118 patients to combined intravenous thrombolysis and endovascular thrombectomy group. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients achieving functional independence at 90 days (defined as score 0-2 on the modified Rankin Scale; range, 0 [no symptoms] to 6 [death]). The noninferiority margin was -10%. Safety outcomes included the incidence of symptomatic intracerebral hemorrhage within 48 hours and 90-day mortality. RESULTS: The trial was stopped early because of efficacy when 234 of a planned 970 patients had undergone randomization. All 234 patients who were randomized (mean age, 68 years; 102 women [43.6%]) completed the trial. At the 90-day follow-up, 63 patients (54.3%) in the endovascular thrombectomy alone group vs 55 (46.6%) in the combined treatment group achieved functional independence at the 90-day follow-up (difference, 7.7%, 1-sided 97.5% CI, -5.1% to ∞)P for noninferiority = .003). No significant between-group differences were detected in symptomatic intracerebral hemorrhage (6.1% vs 6.8%; difference, -0.8%; 95% CI, -7.1% to 5.6%) and 90-day mortality (17.2% vs 17.8%; difference, -0.5%; 95% CI, -10.3% to 9.2%). CONCLUSIONS AND RELEVANCE: Among patients with ischemic stroke due to proximal anterior circulation occlusion within 4.5 hours from onset, endovascular treatment alone, compared with intravenous alteplase plus endovascular treatment, met the prespecified statistical threshold for noninferiority for the outcome of 90-day functional independence. These findings should be interpreted in the context of the clinical acceptability of the selected noninferiority threshold. TRIAL REGISTRATION: Chinese Clinical Trial Registry: ChiCTR-IOR-17013568.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Zi W, Qiu Z, Li F, et al. Effect of Endovascular Treatment Alone vs Intravenous Alteplase Plus Endovascular Treatment on Functional Independence in Patients With Acute Ischemic Stroke: The DEVT Randomized Clinical Trial. JAMA. 2021. PMID: 33464335. doi:10.1001/jama.2020.23523

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。